May 19, 2020
Leading Electrophysiologists (EPs) have performed several preclinical animal studies that support use of the Durablate™ for the successful treatment of VT.
-
In vivo and ex vivo animal models demonstrate that SERF can make the large, transmural lesions required to treat the full extent of VT in the thick ventricle walls
-
Preclinical in vivo animal data include canine, ovine and porcine models.
-
Investigators have concluded that the SERF Ablation Catheter can do the following:
-
Create larger lesions than existing therapeutic catheters in both infarcted and normal tissue
-
Create large, well-defined transmural ablations largely confined to the infarct scar
-
Homogenize the infarct region and eliminate channels of viable myocardium in scar
-
Cure infarcted animals of VT inducibility
-
Deliver large lesions with no detectable additional effects on myocardial hemodynamic function and no evidence of myocardial perforation, wall thinning, or aneurysm formation in chronic animal studies
Durablate™ Ablation In Infarcted Porcine Tissue
